Diflunisal is a nonsteroidal anti-inflammatory drug indicated for stage I and II of transthyretin familial amyloid polyneuropathy (TTR-FAP) according to the European consensus for diagnosis, management, and treatment of this disease (Adams et al., 2016). Here, TTR is linked to familial amyloid neuropathy.